,38,39 Preclinical studies have demonstrated the synergistic antitumor effects of BET inhibitor combinations, such as in ovarian cancer, DLBCL, and CRC cell lines and SCLC xenograft models.2 The gene discussed is DNER; the disease is diffuse large B-cell lymphoma.